Initiation of febuxostat for acute gout flare does not prolong the current episode: a randomized clinical trial.

ABSTRACT:

Objective

Our objective was to determine whether initiation of febuxostat during an acute gout flare prolongs the current episode.

Methods

In this randomized, placebo-controlled, single-blinded, multicentre trial, patients with acute gout flares within 72 h were randomized (1:1) to the placebo and febuxostat (40 mg/day) groups. All patients were administered diclofenac (150 mg/day) for 7 days and then open-labelled on the eighth day. Febuxostat 40 mg daily and diclofenac 75 mg daily were administered from day 8 through 28 for the remission period. The dose of diclofenac was 150 mg/day before remission in both arms, and the original protocol was maintained until remission. The primary outcome was 'days to resolution'.

Results

We randomized 140 patients, 70 into each ar

SUBMITTER: Jia E 

PROVIDER: S-EPMC8409997 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature